HER3-DXd
Pre-clinicalCompleted 0 watching 0 views this weekπ€ Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
Conditions
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
Trial Timeline
β β β
NCT ID
NCT06099639About HER3-DXd
HER3-DXd is a pre-clinical stage product being developed by Daiichi Sankyo for Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06099639. Target conditions include Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06099639 | Pre-clinical | Completed |
| NCT06172478 | Phase 2 | Recruiting |
Competing Products
13 competing products in Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Erlotinib | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| KRN23 | Kyowa Kirin | Phase 2 | 52 |
| SHR6390 + placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Merck | Phase 3 | 77 |
| Venetoclax + Fulvestrant | Roche | Phase 2 | 52 |
| Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine | Roche | Phase 3 | 77 |
| Palbociclib + Everolimus + Exemestane | Pfizer | Phase 1/2 | 40 |
| Palifermin | Swedish Orphan Biovitrum | Phase 1/2 | 40 |
| Crysvita (burosumab-twza) Treatment | Ultragenyx Pharmaceutical | Approved | 80 |
| FDX104 (4% Doxycycline) | Vyne Therapeutics | Phase 2 | 44 |
| ATR-04 | Azitra | Phase 1/2 | 33 |